Skip to content

Pheast Therapeutics

5 viewers · 30d

Total raised

$99.8M

2 filings since 2022 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $24.6M
ROUNDS
2
INVESTORS
7
FOUNDED
2020
HQ
Redwood City, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
5

AI overview

Updated

Pheast Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel immuno-oncology therapies. The company is pioneering a new approach to cancer treatment by targeting innate immune evasion pathways, specifically harnessing the power of macrophages to recognize and eliminate cancer cells. Pheast's innovative approach aims to address the limitations of current immunotherapies and offer solutions for aggressive cancers.

What sets it apart

Targeting innate immune checkpoints

Funding history

2 rounds
Equity+2Oct 7, 2025
Form D
+$24.6M$99.8M total
EquityJan 31, 2022
Form D/A
+$75.3M$75.3M total

Products

1 tracked

PHST001

Monoclonal antibody

PHST001 is an innovative monoclonal antibody targeting CD24, a "don't eat me" signal expressed by various cancer cells, including those found in ovarian and triple-negative breast cancer. By specifically binding to and blocking CD24, PHST001 promotes macrophage-mediated phagocytosis, facilitating the immune system's ability to recognize, engulf, and destroy cancer cells. Preclinical studies have demonstrated the potential of PHST001 to significantly reduce and even eradicate tumors in animal models, highlighting its promise as a novel cancer therapy.

  • Monoclonal antibody
  • Targets CD24
  • Promotes macrophage-mediated phagocytosis
  • Demonstrated preclinical efficacy